772 related articles for article (PubMed ID: 31912280)
21. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
23. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
24. Human amyloid beta and α-synuclein co-expression in neurons impair behavior and recapitulate features for Lewy body dementia in Caenorhabditis elegans.
Huang X; Wang C; Chen L; Zhang T; Leung KL; Wong G
Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166203. PubMed ID: 34146705
[TBL] [Abstract][Full Text] [Related]
25. CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders.
Irwin DJ; Xie SX; Coughlin D; Nevler N; Akhtar RS; McMillan CT; Lee EB; Wolk DA; Weintraub D; Chen-Plotkin A; Duda JE; Spindler M; Siderowf A; Hurtig HI; Shaw LM; Grossman M; Trojanowski JQ
Neurology; 2018 Mar; 90(12):e1038-e1046. PubMed ID: 29467305
[TBL] [Abstract][Full Text] [Related]
26. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
27. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
Sierra M; Gelpi E; Martí MJ; Compta Y
Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
[TBL] [Abstract][Full Text] [Related]
28. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
29. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
[TBL] [Abstract][Full Text] [Related]
30. Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias.
Shellikeri S; Cho S; Cousins KAQ; Liberman M; Howard E; Balganorth Y; Weintraub D; Spindler M; Deik A; Lee EB; Trojanowski JQ; Irwin D; Wolk D; Grossman M; Nevler N
Parkinsonism Relat Disord; 2022 Sep; 102():94-100. PubMed ID: 35985146
[TBL] [Abstract][Full Text] [Related]
31. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
32. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.
Bibl M; Mollenhauer B; Esselmann H; Lewczuk P; Klafki HW; Sparbier K; Smirnov A; Cepek L; Trenkwalder C; Rüther E; Kornhuber J; Otto M; Wiltfang J
Brain; 2006 May; 129(Pt 5):1177-87. PubMed ID: 16600985
[TBL] [Abstract][Full Text] [Related]
33. Imaging amyloid deposition in Lewy body diseases.
Gomperts SN; Rentz DM; Moran E; Becker JA; Locascio JJ; Klunk WE; Mathis CA; Elmaleh DR; Shoup T; Fischman AJ; Hyman BT; Growdon JH; Johnson KA
Neurology; 2008 Sep; 71(12):903-10. PubMed ID: 18794492
[TBL] [Abstract][Full Text] [Related]
34. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People.
de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
J Alzheimers Dis; 2021; 81(3):1295-1309. PubMed ID: 33935098
[TBL] [Abstract][Full Text] [Related]
35. Increased Transforming Growth Factor β2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Aβ42 Load.
Chong JR; Chai YL; Lee JH; Howlett D; Attems J; Ballard CG; Aarsland D; Francis PT; Chen CP; Lai MK
J Alzheimers Dis; 2017; 56(1):157-166. PubMed ID: 27911312
[TBL] [Abstract][Full Text] [Related]
36. Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.
Buddhala C; Campbell MC; Perlmutter JS; Kotzbauer PT
Neurobiol Aging; 2015 Jan; 36(1):476-84. PubMed ID: 25212463
[TBL] [Abstract][Full Text] [Related]
37. Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias.
Bohnen NI; Müller MLTM; Frey KA
Curr Neurol Neurosci Rep; 2017 Aug; 17(10):73. PubMed ID: 28808912
[TBL] [Abstract][Full Text] [Related]
38. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
[TBL] [Abstract][Full Text] [Related]
39. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease.
de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
Aging Clin Exp Res; 2023 Aug; 35(8):1741-1752. PubMed ID: 37264166
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous quantification of tau and α-synuclein in cerebrospinal fluid by high-resolution mass spectrometry for differentiation of Lewy Body Dementia from Alzheimer's Disease and controls.
Viodé A; Epelbaum S; Benyounes I; Verny M; Dubois B; Junot C; Fenaille F; Lamari F; Becher F
Analyst; 2019 Oct; 144(21):6342-6351. PubMed ID: 31553333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]